ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Roche And Genzyme Invest In Biologics

by Ann M. Thayer
October 21, 2013 | APPEARED IN VOLUME 91, ISSUE 42

Roche will invest about $875 million to expand its biologics manufacturing network over five years and create about 500 jobs. The company says it needs additional capacity to support sales of its approved products and ones to emerge from development. In the U.S., Roche will spend about $285 million at its Vacaville and Oceanside, Calif., sites. Another $380 million will go toward expanding and refurbishing its Penzberg, Germany, site, while more than $200 million will be used to build an antibody-drug conjugate facility in Basel, Switzerland (see page 7). Meanwhile, Sanofi’s Genzyme biopharmaceuticals business will spend $80 million to build a downstream processing facility in Framingham, Mass., for its enzyme replacement therapy Fabrazyme.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment